Chemoimmunotherapy of chronic lymphocytic leukemia

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 3, 2007, Pages 479-498

  Tam, Constantine S ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

alemtuzumab; fludarabine; monoclonal antibody; purine analog; rituximab

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; CHIR 12.12; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LUMILIXIMAB; MITOXANTRONE; OXALIPLATIN; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; THALIDOMIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HERPES SIMPLEX; HUMAN; INFECTION; INFECTION RISK; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURINES; VIDARABINE;

EID: 34547961559     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.02.004     Document Type: Review

References (97)

1. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. Journal of the National Cancer Institute 91 (1999) 861-868
2. Call T.G., Phyliky R.L., Noel P., et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clinic Proceedings. Mayo Clinic 69 (1994) 323-328
3. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 (1998) 1165-1171
4. Bosch F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology 119 (2002) 976-984
5. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 23 (2005) 4079-4088
6. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23 (2005) 4070-4078
7. Wierda W., O'Brien S., Faderl S., et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106 (2006) 337-345
8. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
9. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 (2001) 29-35
10. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23 (2005) 2971-2979
11. Keating M.J., Kantarjian H., Talpaz M., et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74 (1989) 19-25
12. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. The New England Journal of Medicine 343 (2000) 1750-1757
13. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347 (1996) 1432-1438
14. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
15. Catovsky D., Richards S., and Hillmen P. Early results from LRF CLL4: a UK multicenter randomized trial. Blood 11 (2005) 212a (abstract 716)
16. Koehi U., Ying Yang L., Nowak B., et al. Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair of damaged DNA. Acute Leukemias VII: Experimental Approaches and Novel Therapies (1998), Springer-Verlag, Berlin 549-555
17. Robertson L.E., O'Brien S., Kantarjian H., et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9 (1995) 943-945
18. Rummel M.J., Kafer G., Pfreundschuh M., et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Annals of Oncology 10 (1999) 183-188
19. O'Brien S.M., Kantarjian H.M., Cortes J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology 19 (2001) 1414-1420
20. Tsimberidou A.M., Keating M.J., Giles F.J., et al. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100 (2004) 2583-2591
21. Tam C.S., Wolf M.M., Januszewicz E.H., et al. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 100 (2004) 2181-2189
22. Gonzalez H., Cazin B., Dighiero G., et al. Fludarabine (FAMP) and cyclophosphamide (CTX) combination in chronic lymphocytic leukemia (CLL). Blood (1998) 2776b (abstract 4193)
23. Hallek M., Schmitt B., Wilhelm M., et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology 114 (2001) 342-348
24. Schiavone E.M., De Simone M., Palmieri S., et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. European Journal of Haematology 71 (2003) 23-28
25. Flinn I.W., Byrd J.C., Morrison C., et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96 (2000) 71-75
26. Cazin B., Maloum K., Divine M., et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 59 patients. Blood 98 supplement (2001) 772a (abstract 3214)
27. Kawai Y., and Plunkett W. DNA repair induced by 4-hydroperxycyclophosphamide permits fludarabine nucleotide incorporation and is associated with synergistic induction of apoptosis in quiescent human lymphocytes. Blood 94 supplement (1999) 655a (abstract 2910)
28. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
29. Flinn I., Kumm E., Grever M., et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood 104 11 (2004) 139a (abstract 475)
30. Seymour J.F., Grigg A.P., Szer J., and Fox R.M. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. Annals of Oncology 12 (2001) 1455-1460
31. Elias L., Stock-Novack D., Head D.R., et al. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 7 (1993) 361-365
32. Schmitt B., Franke A., Schlag R., et al. Fludarabine plus cyclophosphamide and mitoxantrone (FCM) in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Leukemia and Lymphoma 44 supplement 2 (2004) S45 (abstract 83)
33. Mauro F.R., Foa R., Meloni G., et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 87 (2002) 926-933
34. Bosch F., Ferrer A., Villamor N., et al. Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL. ASH Annual Meeting Abstracts 106 (2005) 718
35. Weiss M.A., Maslak P.G., Jurcic J.G., et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 21 (2003) 1278-1284
36. Robak T., Blonski J.Z., Gora-Tybor J., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108 (2006) 473-479
37. Keating M.J., O'Brien S., Kontoyiannis D., et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 43 (2002) 1755-1762
38. Perkins J.G., Flynn J.M., Howard R.S., and Byrd J.C. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 94 (2002) 2033-2039
39. Zhou L.J., and Tedder T.F. CD20 Workship Panel Report. In: Schlossman S.F., Boumsell L., Gilks W., Harlan J.M., Kishimoto T., Morimoto C., Ritz J., Shaw S., and Silverstein R. (Eds). Leucocyte Typing V White Cell Differentiation Antigens (1995), Oxford University, Oxford 511-514
40. Voso M.T., Pantel G., Rutella S., et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 87 (2002) 918-925
41. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16 (1998) 2825-2833
42. Itala M., Geisler C.H., Kimby E., et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology 69 (2002) 129-134
43. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98 (2001) 1326-1331
44. Almasri N.M., Duque R.E., Iturraspe J., et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. American Journal of Hematology 40 (1992) 259-263
45. Manshouri T., Do K.A., Wang X., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507-2513
46. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. Journal of Clinical Oncology 19 (2001) 2165-2170
47. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology 21 (2003) 1746-1751
48. Thomas D.A., O'Brien S., Giles F., et al. Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98 (2001) 364a (abstract 1533)
49. Venugopal P., Sivaraman S., Huang X.K., et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leukemia Research 24 (2000) 411-415
50. Ferrajoli A., O'Brien S., Faderl S., et al. Rituximab plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. Blood 106 (2005) 214a (abstract 721)
51. Gilleece M.H., and Dexter T.M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
52. Osterborg A., Fassas A.S., Anagnostopoulos A., et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology 93 (1996) 151-153
53. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 15 (1997) 1567-1574
54. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
55. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Journal of Clinical Oncology 20 (2002) 3891-3897
56. Ferrajoli A., O'Brien S.M., Cortes J.E., et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98 (2003) 773-778
57. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
58. Hale G., Rebello P., Brettman L.R., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004) 948-955
59. Montillo M., Cafro A.M., Tedeschi A., et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87 (2002) 695-700
60. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
61. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
62. Rai K.R., Byrd J., Peterson B., and Larson R.A. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901. Blood 100 (2002) (abstract 772)
63. Rai K., Byrd J., Peterson B., et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemie (CLL): CALGB Study 19901. Blood 102 (2003) (abstract 2506)
64. Faderl S., Thomas D.A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 (2003) 3413-3415
65. Faderl S., Ferrajoli A., Wierda W., et al. Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 106 (2005) 2963
66. Byrd J.C., O'Brien S., Flinn I., et al. Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts 104 (2004) 2503
67. Crawford D.H., and Catovsky D. In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 80 (1993) 40-44
68. Tong X., Georgakis G.V., Li L., et al. In Vitro Activity of a Novel Fully Human Anti-CD40 Antibody CHIR-12.12 in Chronic Lymphocytic Leukemia: Blockade of CD40 Activation and Induction of ADCC. ASH Annual Meeting Abstracts 104 (2004) 2504
69. Chanan-Khan A., Miller K.C., Takeshita K., et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106 (2005) 3348-3352
70. Chanan-Khan A., Miller K., DiMiceli L., et al. Results of Phase II Study of Lenalidomide (Revlimid) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood 106 (2005) 135a (abstract 447)
71. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clinical Cancer Research 7 (2001) 709-723
72. Chow K.U., Sommerlad W.D., Boehrer S., et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 87 (2002) 33-43
73. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. British Journal of Haematology 114 (2001) 800-809
74. Tam C.S., Wolf M.M., Prince H.M., et al. Fludarabine, Cyclophosphamide and Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukaemia or Indolent Non-Hodgkin Lymphoma Cancer. Cancer 106 (2006) 2412-2420
75. Keating M.J., O'Brien S., Lerner S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves complete response, remission duration and survival as initial therapy of Chronic Lymphocytic Leukemia (CLL). Proceedings of the American Society of Clinical Oncology 23 (2004) (abstract 6565)
76. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology 19 (2001) 2153-2164
77. O'Brien S., Wierda W.G., Faderl S., et al. FCR-3 as Frontline Therapy for Patients with Chronic Lymphocytic Leukemia (CLL). ASH Annual Meeting Abstracts 106 (2005) 2117
78. Faderl S., Wierda W., O'Brien S., et al. A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL <= 70 years (yrs). Journal of Clinical Oncology Meeting Abstracts 24 (2006) 6607
79. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003) 6-14
80. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
81. Schulz H., Klein S.K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100 (2002) 3115-3120
82. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostain, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2007) 405-411
83. Lamanna N., Kalaycio M., Maslak P., et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 24 (2006) 1575-1581
84. Yunus F., George S., Smith J., et al. Phase II multicenter trial of pentostatin and rituximab in patients with previously treated and untreated chronic lymphocytic leukemia. Blood 102 (2003) (abstracts 5168)
85. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
86. Sayala H., Moreton P., Richard J.A., et al. Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). ASH Annual Meeting Abstracts 106 (2005) 2120
87. Elter T., Borshmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology 23 (2005) 7024-7031
88. Catovsky D., Richards S., Matutes E., et al. Response to Therapy and Survival in CLL is influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial. Blood (2004) 104 (abstract 13)
89. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
90. Thornton P.D., Matutes E., Bosanquet A.G., et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Annals of Hematology 82 (2003) 759-765
91. el Rouby S., Thomas A., Costin D., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82 (1993) 3452-3459
92. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85 (1995) 1580-1589
93. Wierda W., O'Brien S., Ferrajoli A., et al. Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. Blood 106 (2005) 213a (abstract 719)
94. Moufarij M.A., Sampath D., Keating M.J., and Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108 (2006) 4187-4193
95. Wierda W., Tsimberidou A., O'Brien S., et al. The combination of oxaliplatin, fludarabine (FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's Transformation and FLU-refractory CLL. Jounal of Clinical Oncology Meeting Abstracts 24 (2006) 6608
96. Kipps T.J. Immune and cell therapy of hematologic malignancies. International Journal of Hematology 76 supplement 1 (2002) 269-273
97. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Experimental Hematology 32 (2004) 28-35